Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.

about

Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.

Item

http://www.wikidata.org/entity/Q38770131

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Treating chronic lymphocytic l ...... y and efficacy considerations.

@en

type

Item

label

Treating chronic lymphocytic l ...... y and efficacy considerations.

@en

prefLabel

Treating chronic lymphocytic l ...... y and efficacy considerations.

@en

P1476

Treating chronic lymphocytic l ...... y and efficacy considerations.

@en

P2093

G Reda

http://www.w3.org/2001/XMLSchema#string

M Sciumè

http://www.w3.org/2001/XMLSchema#string

N Orofino

http://www.w3.org/2001/XMLSchema#string

P2860

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial.

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure-Response in CLL.

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia.

P304

865-873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2016.1165665

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Agostino Cortelezzi

Ramona Cassin

Bruno Fattizzo

P577

2016-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26967902

http://www.w3.org/2001/XMLSchema#string